Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studiare gli adattamenti metabolici e psicologici in uno studio clinico (IMPACT)

16 novembre 2026 aggiornato da: Leonard Epstein, State University of New York at Buffalo

Effetto dei tempi dei pasti e cambiamenti dietetici sui fattori metabolici e comportamentali coinvolti nel paradosso di insicurezza alimentare

This study aims to explore how food insecurity, a lack of consistent access to enough food, may lead to changes in the body that make it harder to lose weight. The investigators are testing whether providing women experiencing food insecurity with a stable, healthy, and personalized meal plan can improve their metabolism and reduce their motivation to eat unhealthy foods. The hypothesis is that addressing food insecurity with a predictable diet can lower a person's respiratory quotient (a measure of how the body uses energy), promote fat burning, and improve overall health. This research will improve the understanding for how food insecurity contributes to obesity and may lead to better solutions for managing weight in individuals facing these challenges.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Women who experience food insecurity have unpredictable access to food and often miss meals and go hungry, but paradoxically are at a 50% greater risk for developing obesity than women who are food secure. This is due in part to metabolic and behavioral factors involved in food insecurity. Research suggests unpredictable access to food is associated with: 1) a high respiratory quotient (RQ) indicative of substrate oxidation that favors storage of fat and burning of carbohydrates; 2) an increase in fuel efficiency and a reduced thermic effect of food (TEF); 3) higher relative reinforcing efficacy of food (RREFOOD), due in part to periodic food deprivation that results from unpredictable access to food and being hungry, and 4) a short temporal window that involves making decisions that focus on meeting immediate versus long-term goals, as assessed by delay discounting (DD). While people with food insecurity and obesity should modify their diet, an RQ that favors storage of fat coupled with a reduced TEF, high RREFOOD and high DD may compromise the effects of traditional dietary approaches to weight loss. The goal of this pilot study is to examine the effects of providing a personalized, stable, predictable, low carbohydrate, low glycemic index, high protein, low energy dense diet on changes in metabolic and behavioral factors that characterize low-income women with food insecurity who have obesity, using a novel stepped wedge design. This work extends our research on behavioral and metabolic factors involved in food insecurity, and will provide strong pilot data for a randomized, controlled trial of a novel dietary approach that target factors involved in food insecurity and obesity that can improve weight control and reduce cardiometabolic risk factors. The investigators expect to screen at least 60 women, with an estimated screen failure rate of 80%. A goal for this pilot project is to provide effect sizes for future studies. The sample size was determined based on feasibility constraints, with the understanding that these results will serve as pilot data for a larger, fully powered randomized controlled trial.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

12

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New York
      • Buffalo, New York, Stati Uniti, 14221
        • Farber Hall G56

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Woman between the ages of 18-45.
  • Premenopausal.
  • Obese (BMI ≥ 30).
  • Diagnosed with prediabetes (HbA1c: 5.7%-6.4%).
  • Experiencing food insecurity (score of 2-6 on the six-item food insecurity questionnaire).
  • Income below 300% of the household federal poverty threshold.
  • Lives alone.

Exclusion Criteria:

  • Actively planning to become pregnant (e.g., individuals trying to conceive or undergoing fertility treatment, based on self-report).

  • Delivered a baby within the past 6 months (self-report).

  • Non-ambulatory (e.g., individuals unable to walk independently or requiring a wheelchair for mobility).

  • Intellectual impairment that would impact treatment adherence.

  • Unmanaged mood disorders, substance use disorders, personality disorders, or a history of eating disorders, including:

    • Generalized anxiety disorder.
    • Depression.
    • Alcohol dependence.
    • Schizophrenia.
    • Anorexia nervosa, bulimia, or binge eating disorder within the past 6 months.
  • Recent weight loss exceeding 5% of body weight within the past 6 months (self-report).

  • Food allergies to study-related foods, including dairy, soy, nuts, or gluten.

  • History of bariatric surgery or GLP-1 agonist use (self-report).

  • Inability to read or write in English (self-report).

  • Planned relocation out of the study area during the study timeframe (self-report).

  • Uncontrolled diabetes (HbA1c > 9%) or hypertension (blood pressure > 160/100 mmHg), based on self-report or screening visit measurements.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control phase

During this phase, participants are told to maintain typical behaviors and not change any normal patterns of activity/eating.

Sperimentale: Treatment phase

There are two components to the treatment:

Food provisioning: The food provisioning component will consist of bi-weekly home deliveries of three meals a day. The number of calories in the provided meals for each day will be personalized based on each participant's resting metabolic rate. Caloric targets for each participant will be 20% of TDEE as this translates to ~1-2 pounds of weight loss per week. Diets composition will also be tailored to help improve TEF and RQ.

Behavioral Skills Training: This will be based on an evidence-based behavioral weight-loss program developed in our lab. This treatment has shown clinically significant weight loss with positive effects sustained over 10-years. The specific includes lessons on self-monitoring, developing alternatives to foods, meal-planning, goal setting, episodic future thinking, physical activity, and self-reinforcement.

7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.

3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in body weight
Lasso di tempo: Through study completion, an average of 25 weeks

measured in kgs using a weight scale.

Through study completion, an average of 25 weeks
change in HBA1C
Lasso di tempo: Through study completion, an average of 25 weeks.

measured via a finger-prick blood sample analyzed using a point-of-care device

Through study completion, an average of 25 weeks.
Change in respiratory quotient
Lasso di tempo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
change in TEF
Lasso di tempo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
Change in delay discounting
Lasso di tempo: Through study completion, an average of 25 weeks.

will be measured using the adjusting amount delay discounting task that presents participants with choices between a fraction of the total delayed amount of money now or the full amount ($100 &/ $1000) at a future delayed time for five different periods from 30 days, 180 days, 365 days (1 year), 1095 days (3 years), 1825 days (5 years) (order randomized).

Through study completion, an average of 25 weeks.
Change in RRE
Lasso di tempo: Through study completion, an average of 25 weeks.

RRE will be assessed through a survey that will use participants' preferred snack foods that are classified as either hyperpalatable or healthy. Scores have no fixed minimum or maximum, as they are determined by the highest ratio completed before the participant stops working for the food reward. Higher scores indicate greater reinforcing efficacy and a stronger motivational drive for the food reward, which is considered a worse outcome in this context.

Through study completion, an average of 25 weeks.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
change in stress
Lasso di tempo: Through study completion, an average of 25 weeks.

measured using the Perceived Stress Scale. The Perceived Stress Scale is a validated 10-item questionnaire that measures the perception of stress over the past month. Scores range from 0 to 40, where higher scores indicate greater perceived stress and worse outcomes.

Through study completion, an average of 25 weeks.
change in physical activity
Lasso di tempo: Through study completion, an average of 25 weeks.

measured using a Fitbit activity monitor

Through study completion, an average of 25 weeks.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 luglio 2025

Completamento primario (Effettivo)

30 giugno 2026

Completamento dello studio (Effettivo)

30 settembre 2026

Date di iscrizione allo studio

Primo inviato

17 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

23 gennaio 2025

Primo Inserito (Effettivo)

30 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 gennaio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STUDY00008988

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The investigators plan to share de-identified individual participant data (IPD) with other researchers to promote transparency, reproducibility, and the advancement of scientific knowledge.

Periodo di condivisione IPD

The IPD and supporting information (Study Protocol, SAP, ICF, and Analytic Code) will be made available no later than 12 months after the publication of the primary study results or 12 months after the final study completion date (November 1, 2025), whichever comes first. Therefore, the anticipated start date for data availability is November 1, 2026. The IPD and supporting information will remain available for a period of 5 years from the start date, allowing sufficient time for secondary analyses and collaborative research. The anticipated end date is November 1, 2031.

Criteri di accesso alla condivisione IPD

Qualified Researchers: Access will be granted to researchers affiliated with academic, non-profit, or governmental institutions conducting non-commercial research. Researchers must demonstrate a legitimate scientific purpose for using the data.

Individual Participant Data (IPD):

De-identified data for all primary and secondary outcome measures (e.g., respiratory quotient, thermic effect of food, body weight, relative reinforcing value of food, and delay discounting).

Accompanying metadata and codebooks for proper interpretation of the data.

Supporting Information:

Study Protocol: Detailed description of the study design and methodology. Statistical Analysis Plan (SAP): Comprehensive explanation of the planned statistical analyses for all outcomes.

Informed Consent Form (ICF): Template of the consent form used during the study.

Analytic Code: Scripts used for data cleaning and statistical analyses, enabling reproducibility of results.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .